Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Convertible loan notes extension

13 Dec 2011 12:44

RNS Number : 8814T
PuriCore Plc
13 December 2011
 



PuriCore plc

("PuriCore" or the "Company")

 

Extension of Repayment Date of Convertible Loan Notes

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 13 December 2011 - PuriCore (LSE: PURI), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces an extension of the repayment date in relation to the convertible loan notes issued by the Company on 14 June 2010 (the "Convertible Loan Notes"), details of which were announced and set out in a circular to shareholders on 28 May 2010.

 

Following the announcement on 21 October 2011 that the Company was exploring a number of options regarding the Convertible Loan Notes, PuriCore has reached an agreement with the requisite majority of holders of the Convertible Loan Notes for a two-year extension of the repayment date, which will now be 31 December 2013. The Convertible Loan Notes, amounting to £7.95 million, were due to be repaid on 31 December 2011, subject to the holders having the right to convert all or part of their holdings into ordinary shares of the Company at a price (following the consolidation of the share capital on 14 June 2010) of 75p per share. There have otherwise been no other changes to the terms of the Convertible Loan Notes.

 

The Company is currently negotiating additional funding lines and is considering raising further capital. All new funding will be used for market development and general working capital purposes. Any issue of new equity may be undertaken in conjunction with a renegotiation of the Convertible Loan Notes to include a reduction in the conversion price (if appropriate) to reflect market conditions and to provide an incentive for early conversion. Any significant issue of new equity and proposed changes to the conversion terms of the Convertible Loan Notes will be subject to shareholder approval.

 

Enquiries:

FTI Consulting

PuriCore

Susan Quigley

Chris Wightman

Ben Brewerton

Executive Chairman

+44 (0) 20 7831 3113

+44 (0) 20 7290 3440

 

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFSFFVLVLIL
Date   Source Headline
2nd Nov 20097:00 amRNSDarren Weiss promoted to CFO & Executive Director
15th Sep 20099:47 amRNSHolding(s) in Company
2nd Sep 20092:32 pmRNSHolding(s) in Company
27th Aug 20097:00 amRNSTotal Voting Rights
25th Aug 20094:18 pmRNSHolding(s) in Company
25th Aug 20097:00 amRNSPuriCore New $2.1 Million Facility
25th Aug 20097:00 amRNSInterim Results
5th Aug 20097:00 amRNSTrading Statement
5th Aug 20097:00 amRNSAcquisition and Placing
4th Aug 20097:00 amRNSBlocklisting Interim Review
24th Jul 20094:40 pmRNSSecond Price Monitoring Extn
24th Jul 20094:35 pmRNSPrice Monitoring Extension
10th Jul 20094:40 pmRNSSecond Price Monitoring Extn
10th Jul 20094:35 pmRNSPrice Monitoring Extension
7th Jul 20094:40 pmRNSSecond Price Monitoring Extn
7th Jul 20094:35 pmRNSPrice Monitoring Extension
17th Jun 20097:00 amRNSPresenting at Piper Jaffray European Conference
5th Jun 200911:20 amRNSResult of AGM
28th May 20091:16 pmRNSUS retailer extends use of Sterilox systems
27th May 20097:00 amRNSAnnual Information Update
30th Apr 20095:01 pmRNSHolding(s) in Company
30th Apr 20097:00 amRNSSterilox Effective against Human/Animal Influenza
28th Apr 20097:01 amRNSQ1 Interim Management Statement
28th Apr 20097:00 amRNSFinal Results
17th Feb 200910:45 amRNSHolding(s) in Company
10th Feb 20094:28 pmRNSDirector/PDMR Shareholding
9th Feb 20097:00 amRNSDirector/PDMR Shareholding
6th Feb 200910:27 amRNSHolding(s) in Company
4th Feb 20099:28 amRNSBlocklisting Interim Review
3rd Feb 20099:41 amRNSDirector/PDMR Shareholding
2nd Feb 20097:00 amRNSTrading Statement
2nd Jan 20097:00 amRNSDirector/PDMR Shareholding
29th Dec 20084:34 pmRNSDirector/PDMR Shareholding
19th Dec 20084:43 pmRNSSecond Price Monitoring Extn
19th Dec 20084:36 pmRNSPrice Monitoring Extension
12th Nov 20085:01 pmRNSDirector/PDMR Shareholding
3rd Nov 20087:00 amRNSNotification of PDMR Interest - Option Award
24th Oct 20087:00 amRNSReceives an order from Safeway
13th Oct 20087:01 amRNSBoard and Organisational Changes
13th Oct 20087:00 amRNSInterim Management Statement
1st Oct 20087:00 amRNSRaises $9.74 million
11th Sep 20085:51 pmRNSHolding(s) in Company
4th Sep 20085:51 pmRNSHolding(s) in Company
3rd Sep 20085:26 pmRNSHolding(s) in Company
29th Aug 20082:44 pmRNSPDMR Dealings
29th Aug 20087:00 amRNSTotal Voting Rights
29th Aug 20087:00 amRNSInterim Results
26th Aug 20083:02 pmRNSResult of General Meeting
22nd Aug 20087:00 amRNSResult of Open Offer
4th Aug 20088:27 amRNSBlocklisting six monthly retu

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.